53.18

1.48% -0.80

After Hours: 53.18

Biomarin Pharmaceutical Inc (BMRN)

Overview News Price History Option Chain Financials Discussions Forecast

Biomarin Pharmaceutical Inc stock is traded at $53.18, with a volume of 1.08M. It is down -1.48% in the last 24 hours and down -1.68% over the past month. BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.

Previous Close:

$53.98

Open:

$53.87

24h Volume:

1.08M

Relative Volume:

0.54

Market Cap:

$10.28B

Revenue:

$3.24B

Net Income/Loss:

$348.90M

P/E Ratio:

29.85

EPS:

1.7817

Net Cash Flow:

$717.02M

1W Performance:

-2.67%

1M Performance:

-1.68%

6M Performance:

-2.39%

1Y Performance:

-15.24%

1-Day Range:

$52.88

$54.32

1-Week Range:

$52.88

$55.57

52-Week Range:

$50.76

$66.28

Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile

Name

Biomarin Pharmaceutical Inc

Sector

Healthcare (1108)

Industry

Biotechnology (619)

Phone

(415) 506-6700

Address

105 DIGITAL DRIVE, NOVATO, CA

Employee

3,221

Twitter

Next Earnings Date

2026-05-07

Latest SEC Filings

BMRN's Discussions on Twitter

Compare BMRN vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BMRN Biomarin Pharmaceutical Inc	53.18	10.43B	3.24B	348.90M	717.02M	1.7817
VRTX Vertex Pharmaceuticals Inc	430.29	110.67B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	751.57	80.98B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	780.25	49.00B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	305.54	41.87B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	300.80	33.28B	5.36B	287.73M	924.18M	2.5229

Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-28-26	Resumed	Barclays	Overweight
Jan-20-26	Upgrade	Canaccord Genuity	Hold → Buy
Dec-03-25	Downgrade	Leerink Partners	Outperform → Market Perform
Nov-06-25	Downgrade	Stifel	Buy → Hold
Sep-08-25	Initiated	H.C. Wainwright	Neutral
Sep-03-25	Initiated	Raymond James	Outperform
Jul-03-25	Resumed	Morgan Stanley	Overweight
Feb-24-25	Upgrade	Oppenheimer	Perform → Outperform
Nov-15-24	Initiated	Wolfe Research	Outperform
Oct-30-24	Downgrade	William Blair	Outperform → Mkt Perform
Oct-10-24	Resumed	Raymond James	Outperform
Aug-20-24	Upgrade	Bernstein	Mkt Perform → Outperform
May-17-24	Downgrade	Robert W. Baird	Outperform → Neutral
May-14-24	Initiated	Evercore ISI	Outperform
Nov-15-23	Initiated	Wells Fargo	Overweight
Oct-23-23	Upgrade	Bernstein	Underperform → Mkt Perform
Sep-28-23	Initiated	Raymond James	Mkt Perform
Sep-18-23	Initiated	UBS	Buy
Jul-27-23	Initiated	Scotiabank	Sector Perform
Jul-05-23	Upgrade	BMO Capital Markets	Market Perform → Outperform
Jun-14-23	Resumed	Credit Suisse	Outperform
Mar-21-23	Initiated	Bernstein	Underperform
Feb-22-23	Downgrade	Oppenheimer	Outperform → Perform
Feb-21-23	Initiated	Citigroup	Neutral
Jan-30-23	Initiated	BMO Capital Markets	Market Perform
Jan-18-23	Initiated	Canaccord Genuity	Hold
Oct-31-22	Upgrade	Oppenheimer	Perform → Outperform
Jul-13-22	Initiated	Cantor Fitzgerald	Overweight
Jun-13-22	Resumed	Wedbush	Neutral
Apr-25-22	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Nov-22-21	Upgrade	William Blair	Mkt Perform → Outperform
Oct-07-21	Resumed	Jefferies	Buy
Sep-09-21	Upgrade	Stifel	Hold → Buy
Jun-04-21	Resumed	Robert W. Baird	Outperform
Apr-26-21	Resumed	Credit Suisse	Outperform
Mar-04-21	Resumed	Guggenheim	Buy
Mar-01-21	Upgrade	Evercore ISI	In-line → Outperform
Aug-20-20	Downgrade	Citigroup	Buy → Neutral
Aug-20-20	Downgrade	William Blair	Outperform → Mkt Perform
Aug-19-20	Downgrade	Evercore ISI	Outperform → In-line
Aug-19-20	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Aug-19-20	Downgrade	Stifel	Buy → Hold
Jul-08-20	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jul-06-20	Reiterated	Citigroup	Buy
Jan-28-20	Initiated	BMO Capital Markets	Market Perform
Jan-27-20	Initiated	BMO Capital Markets	Market Perform
Jan-24-20	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Nov-27-19	Upgrade	Barclays	Equal Weight → Overweight
Nov-12-19	Initiated	SunTrust	Buy
Oct-17-19	Resumed	BofA/Merrill	Buy
May-23-19	Resumed	Citigroup	Buy
Apr-09-19	Resumed	Raymond James	Outperform
Jan-02-19	Downgrade	Raymond James	Outperform → Mkt Perform
Dec-14-18	Initiated	Wolfe Research	Outperform
Oct-01-18	Initiated	Cantor Fitzgerald	Overweight
Aug-07-18	Reiterated	Stifel	Buy
Aug-03-18	Reiterated	Stifel	Buy

View All

Biomarin Pharmaceutical Inc Stock (BMRN) Latest News

Apr 23, 2026

BioMarin set to acquire Amicus after regulatory clearance - TipRanks

Apr 23, 2026

BioMarin receives French clearance for Amicus merger, closing expected soon - Investing.com

Apr 23, 2026

According to the latest public documents from the U.S. Securities and Exchange Commission (SEC), the French regulatory authority officially approved the foreign direct investment (FDI) permit for the merger between Biomarin Pharmaceutical Inc and Amicus T - Bitget

Apr 23, 2026

BioMarin clears final French FDI hurdle, merger with Amicus expected to close April 27, 2026 - TradingView

Apr 23, 2026

BioMarin (BMRN) wins French FDI clearance ahead of Amicus merger close - Stock Titan

Apr 23, 2026

Is It Time To Reconsider BioMarin Pharmaceutical (BMRN) After Multi Year Share Price Weakness - Sahm

Apr 23, 2026

BioMarin’s BMN 333 Takes On Vosoritide in High Stakes Achondroplasia Trial - TipRanks

Apr 23, 2026

BioMarin Pharmaceutical: Ian T. Clark Named As Chair - Pulse 2.0

Apr 23, 2026

California biotech BioMarin will pay $4.8 billion for Amicus Therapeutics, a rare-disease company with a presence in Philadelphia - MSN

Apr 23, 2026

Apr 21, 2026